clarification, took place in robust but usually good natured encounters over the telephone or in informal meetings rather than in official communications. Manufacturers seemed to appreciate this informal approach which perhaps did something to influence the statutory Safety of Medicines Committee (some of the members were originally the same) when It succeeded the Safety of Drugs Committee in 1969.Rejections of new medicines were relatively few and constituted a comparatively minor part of the Committee's function. More important was the persuasion of manufacturers to alter their intentions, to modify their promotional claims or to issue warnings to doctors when a medicine seemed to be developing undue or unexpected adverse reactions. In addition, the mere existence of the Committee may have tightened up standards. It never took more than four months after an application had been filed either for clinical trial or marketing of a new chemical agent for a decision to be given and new formulations of standard remedies were dealt with within a few weeks.
Of course it was much easier to solve problems with expedition and good temper when the Committee was not under the Law, for it could make its own case-law as it went along according to circumstances and common sense. Besides the Safety of Drugs Committee was only concerned with the safety of a new drug for the purpose for which it was to be used. On the other hand, the statutory Committee for the Safety of Medicines has to deal in addition with efficacy as well as safety. It has to provide an inspecting and licensing system to ensure the best conditions for the manufacture, storage and distribution of medicines, and to ensure that drugs coming from abroad conform to the standards of the British Pharmacopoeia. It provides that all medicine must be sold from pharmacies except for some relatively innocuous home remedies which appear on a General Sales List, and ensures that promotional literature is consistent with the terms of a data sheet approved by the Safety Committee. Another list enumerates those medicines obtainable by Prescription Only, and provides that a Committee will review all those medicines given Licences of Right which had been already on the market prior to the onset of the licensing period. A similar Committee on veterinary products advises on veterinary medicines and medicated animal feeding stuffs.
No wonder it takes longer than three or four months for the Statutory Committee to give its decisions. This is not as long as the six to nine years often taken by the Food and Drugs Authority in the USA where ultimate power to license medicines rests with the full-time professional civil servants of the FDA, whose careers do depend on their decisions which are subject to formidable grillings by congressional committees.
Officials charged with approving or disapproving a new drug can make two kinds of mistake: they can approve a drug which turns out to be unexpectedly toxic; or refuse approval of one that could have been life-saving with few adverse effects. If they make the first mistake their folly will be emblazoned in the public media and disgrace will follow; if the second few will know of it and those whose lives might have been saved will not be there to protest. No wonder officials are chary of approving a new drug and continually think up yet another test on it just to be on the safe side. IIi their extreme caution the FDA do sometimes set a barrier to bona fide research and progress and the number of new drugs produced by the industry in the USA has greatly diminished in recent years. It is ironical that the USA, the home of free enterprise, should have been far more rigid and bureaucratic in their control of drugs than we have been in this country, the birthplace of so-called socialized medicine. We must not, however, be too complacent. We now tend to do tomorrow what the USA does today. It already takes a very long time to get a new drug licensed for clinical trial on human volunteers or patients in this country owing to the very prolonged carcinogenic and teratogenic tests on animals that are now required.
The pharmaceutical industry seems to possess most of the conventional commercial virtues: a high rate of investment, reasonably satisfactory labour relations, a great emphasis on fundamental as well as on applied research, generous contributions to charity, to the advancement of medical, agricultural and veterinary science and a brilliant record ofeconomic success which has contributed considerably to our export drive in this country. Yet few other industries have been subjected to so much adverse criticism, jealous political antagonism or stringent bureaucratic controls. The problems of the economics, profits and ethics of the industry are not simple but very complex and it would take too long to discuss them. In some future Utopia non-profit-making organizations may achieve the same brilliant results without side effects. Till then we must take the world as we find it and remember that the State-owned industries of the USSR and its satellites have hardly produced a single new therapeutic agent of real importance.
It is fairly safe to conclude that by the end of the century social security schemes of one kind or another will be universal in civilized countries providing medical care for everyone. Consequently the State will everywhere become the chief customer of the pharmaceutical industry. Under such circumstances a clash of interests is likely to occur. On the one hand powerful international companies may seek to free themselves from what they believe to be shackling controls, curtailing their profits, expansion, research and innovation. On the other, governments, often increasingly left-wing in outlook and yielding sometimes to irrational public demands to ensure the complete safety of drugs (which is impossible) and to limit their cost, may impose increasingly rigid controls on their price and promotion by a state-owned industry, as has already happened to a very limited extent in Sweden and more particularly in India. All this would be most unfortunate. Government, industry and the medical profession have each so much to contribute provided their efforts are harmonized. In a minute way this harmonization was perhaps shown to be a practical proposition in the time of the voluntary Safety of Drugs Committee.
Inadequate legislation can prejudice public safety. Excessive legislation can also be prejudicial. It would be a pity if in our desire to improve the health of the public an excessive regulation of medicines is allowed to develop.
